Skip to nav Skip to content

Moffitt Cancer Center is one of the five institutions selected as a Cell Therapies Processing Facility by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH). This exclusive group includes the only NHLBI-approved facilities to produce cell-based therapies for scientific research. As part of the NHLBI PACT group, Moffitt is manufacturing human cells that will be used to help develop early-stage clinical trials to evaluate the safety and effectiveness of new therapies.

The goal of the PACT program is to advance cellular therapy research in the areas of organs and biologic systems, damaged and diseased tissue regeneration, as well as create targeted treatments for serious diseases without effective therapies. The cell processing facilities are charged with implementing the rapid, safe and consistent transition of innovative treatment concepts to clinical practice, as well as supplying clinical-grade products produced in a manner that is compliant with applicable regulatory requirements.

The NHLBI provides each PACT group member with infrastructure funding. There is also the opportunity to receive additional funds as members receive and complete cell-based therapy requests from institutions across the country.

The principal investigator of the proposal is Dr. Linda L. Kelley, senior member in the Department of Immunology. Drs. James Mule and Claudio Anasetti are co-investigators in this award.